Navigation Links
CRF announces featured clinical trials to be presented at TCT 2009 in San Francisco
Date:8/20/2009

WHAT: A series of Featured Clinical Trials will be presented at Transcatheter Cardiovascular Therapeutics (TCT), in addition to late-breaking clinical trials. These featured clinical trials represent groundbreaking research and will yield data and insight that will further the field of interventional cardiology.

WHEN: The TCT Featured Clinical Trials will be presented on September 24, 2009 from 2:00 6:00 pm.

Session I. Drug-Eluting Stents

  • ZEST: Final Angiographic and IVUS Results From a Large-Scale Randomized Trial of Zotarolimus-Eluting, Sirolimus-Eluting and Paclitaxel-Eluting Stents
    Cheol Whan Lee, MD
  • CEREA-DES: A Prospective Randomized Trial of Corticosteroids in Patients Undergoing Stent Implantation
    Flavio L Ribichini, MD
  • STATINS PRE-PCI: A Prospective Randomized Trial of Statins Prior to Stent Implantation in Patients with Stable Angina
    Josef Veselka, MD, PhD
  • NEVO RES-ELUTION I QOL: Formal Quality-of-Life Assessment from a Prospective Randomized Trial of a Novel Sirolimus-Eluting Stent and a Paclitaxel-Eluting Stent
    John A. Spertus, MD
  • CILOTAX: A Prospective, Randomized, Controlled Trial of a Stent Eluting Cilostazol and Paclitaxel
    Cheol Whan Lee, MD
  • BIOFREEDOM: A Prospective Randomized Trial of a Polymer-Free Biolimus A9-Eluting Stent
    Eberhard Grube, MD

Session II. ACS Therapies and Novel Imaging Approaches

  • MISTRAL: A Prospective Randomized Trial of Ambulance-Initiated vs. Cath Lab-Initiated Intravenous Abciximab in Patients with STEMI
    Patrick Ohlmann, MD, PhD
  • COCKTAIL: A Prospective Randomized Trial of Intracoronary Abciximab Infusion in Patients with Thrombotic Lesions Assessed by OCT Francesco Prati, MD
  • NO REFLOW: A Prospective Randomized Trial of Intracoronary vs. Guide Catheter Infusion of Nitrates vs. Calcium Channel Blockers in Patients with No Reflow After Primary PCI in STEMI
    Junbo Ge, MD
  • OCTAMI: A Prospective Randomized Trial of Zotarolimus-Eluting and Bare-Metal Stents in STEMI Assessed by OCT
    Giulio Guagliumi, MD

Session III. End-Stage, Structural Heart and Endovascular Intervention

  • The Canadian Transcatheter Aortic Valve Implantation Program: Acute and Late Follow-up from a Multicenter Consecutive Series of Patients with Inoperable or High-Surgical Risk Aortic Stenosis
    Josep Rodes-Cabau, MD
  • CROSS-CLI: A Prospective Multicenter Registry of Ultrasound-Facilitated Recanalization of Peripheral Chronic Total Occlusions
    David E. Allie, MD
  • ARMOUR: A Prospective, Nonrandomized Study of the Mo.Ma Proximal Cerebral Protection Device in High Surgical Risk Subjects Undergoing Carotid Artery Stenting
    Gary M. Ansel, MD
  • PROVASA: A Prospective, Randomized, Placebo-Controlled Trial of Intra-Arterial Progenitor Cell Transplantation of Bone Marrow Mononuclear Cells in Patients with Peripheral Arterial Occlusive Disease
    Dirk H. Walter, MD
  • ACT34-CMI: One-Year Results from a Prospective, Randomized, Placebo-Controlled Phase II Trial of CD34+ Cells in Patients with Refractory Angina
    Douglas W. Losordo, MD

WHERE: The Moscone Center San Francisco, CA


'/>"/>

Contact: Judy Romero
jromero@crf.org
212-851-9311
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. ESCO Announces Major Contract Award for Its Thermoforming Business
2. CSC Announces Agreement to Provide Billing Service to Colorado West Dermatology
3. Florida Spine Surgeon Alfred Bonati, M.D. Announces Results of National Poll Showing America's Doctors Oppose a Government-Run Health Care Plan
4. AMDL Inc. Announces Second Quarter 2009 Financial Results
5. Chindex International, Inc. Announces New CDC Contract
6. Anthem Blue Cross and Blue Shield in Maine Announces Decision to Cover H1N1 Vaccine Administration
7. Expresso Fitness(R) Announces $6M Series D Funding
8. Exsulin Corporation Announces Publication of Phase 2 Trial Results for Novel Islet Regeneration Treatment in Type 1 & Type 2 Diabetes
9. Anthem Blue Cross and Blue Shield in New Hampshire Announces Decision to Cover H1N1 Vaccine Administration
10. DURECT Announces License of ADHD Drug Candidate in Selected Asian and South Pacific Countries to Orient Pharma
11. American Council on Exercise (ACE) Announces Top Ten Tips to Avoid the Freshman 15
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... July 24, 2017 , ... ... that already work hand-in-hand on an Innovation Collaboration program, have signed a five-year ... experience and cost of the care members and patients receive. The agreement also ...
(Date:7/24/2017)... California (PRWEB) , ... July 24, 2017 , ... ... of autologous fat (adipose) transfer systems announces the issuance of United States Patent ... patent) for its adipose filtration technology. The '398 and '324 patents cover ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... ... August 13-17 in National Harbor, MD. This year's theme focuses on the new ... principal benchmarks for quality and integrity in testing and calibration will be changed. ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... ... sleep management solution focused on delivering end-to-end sleep health care at ... , Recent literature shows that adherence rates for positive airway pressure (PAP) therapy, ...
(Date:7/24/2017)... ... July 24, 2017 , ... A Southern California-based author has ... sexual abuse, and how she has overcome them. “Forbidden Memories: A Memoir,” by author ... and how she has risen above. , In “Memories,” readers get a firsthand look ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)...  The global market for liquid biopsy diagnostic and ... in 2016.  Although in early stages, the global market ... as a result of the gradual shift towards personalized ... of a significant number of new liquid biopsy tests ... biomarkers to guide treatment decisions. ...
(Date:7/10/2017)... CLEVELAND , July 10, 2017  US medical ... billion in 2021, according to Medical Equipment ... released by Freedonia Focus Reports. Continued increases in demand ... the aging of the population and supported by gains ... associated equipment and supplies. New product introductions will also ...
(Date:7/10/2017)... PARK, N.C. , July 10, 2017 ... $5m Convertible Note to support the development of CRISPR-Cas3 ... Tencent Holdings Limited, a leading Chinese Internet services provider, ... funding will advance multiple infectious disease product programs targeting ... Founded by Dr. Rodolphe ...
Breaking Medicine Technology: